Patents by Inventor Robert Kuehl

Robert Kuehl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Heterocyclic compounds and their uses
    Patent number: 11884630
    Abstract: Provided are certain pharmaceutical formulations of omecamtiv mecarbil and methods for their preparation and use.
    Type: Grant
    Filed: June 8, 2022
    Date of Patent: January 30, 2024
    Assignee: CYTOKINETICS, INC.
    Inventors: Mingda Bi, Robert Kuehl
  • PHARMACEUTICAL FORMULATIONS OF A BRUTON'S TYROSINE KINASE INHIBITOR
    Publication number: 20220331252
    Abstract: Described herein are pharmaceutical formulations of Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one. Also disclosed are methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: November 29, 2021
    Publication date: October 20, 2022
    Inventors: Ching W. Chong, Robert Kuehl, Heow Tan, Harisha Atluri
  • HETEROCYCLIC COMPOUNDS AND THEIR USES
    Publication number: 20220298114
    Abstract: Provided are certain pharmaceutical formulations of omecamtiv mecarbil and methods for their preparation and use.
    Type: Application
    Filed: June 8, 2022
    Publication date: September 22, 2022
    Inventors: Mingda BI, Robert KUEHL
  • Heterocyclic compounds and their uses
    Patent number: 11384053
    Abstract: Provided are certain pharmaceutical formulations of omecamtiv mecarbil and methods for their preparation and use.
    Type: Grant
    Filed: September 23, 2019
    Date of Patent: July 12, 2022
    Assignee: CYTOKINETICS, INC.
    Inventors: Mingda Bi, Robert Kuehl
  • Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor
    Patent number: 10828259
    Abstract: Described herein are pharmaceutical formulations of Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one. Also disclosed are methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Grant
    Filed: April 10, 2020
    Date of Patent: November 10, 2020
    Assignee: Pharmacyclics LLC
    Inventors: Ching W. Chong, Robert Kuehl, Heow Tan, Harisha Atluri
  • HETEROCYCLIC COMPOUNDS AND THEIR USES
    Publication number: 20200277261
    Abstract: Provided are certain pharmaceutical formulations of omecamtiv mecarbil and methods for their preparation and use.
    Type: Application
    Filed: September 23, 2019
    Publication date: September 3, 2020
    Inventors: Mingda Bi, Robert Kuehl
  • PHARMACEUTICAL FORMULATIONS OF A BRUTON'S TYROSINE KINASE INHIBITOR
    Publication number: 20200237673
    Abstract: Described herein are pharmaceutical formulations of Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one. Also disclosed are methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: April 10, 2020
    Publication date: July 30, 2020
    Inventors: Ching W. Chong, Robert Kuehl, Heow Tan, Harisha Atluri
  • Heterocyclic compounds and their uses
    Patent number: 10421726
    Abstract: Provided are certain pharmaceutical formulations of omecamtiv mecarbil and methods for their preparation and use.
    Type: Grant
    Filed: March 20, 2018
    Date of Patent: September 24, 2019
    Assignee: AMGEN INC.
    Inventors: Mingda Bi, Robert Kuehl
  • NOVEL FORMULATIONS OF A BRUTON'S TYROSINE KINASE INHIBITOR
    Publication number: 20190282578
    Abstract: Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including novel pharmaceutical formulations thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: October 19, 2018
    Publication date: September 19, 2019
    Inventors: Harisha Atluri, Ching Wah Chong, Robert Kuehl, Cassandra Shu, Pearl Shwe-Cho Tay, James Francis Hulvat, Alexander Jacob McVey, Ryan Mitchell Minikis
  • PHARMACEUTICAL FORMULATIONS OF A BRUTONS TYROSINE KINASE INHIBITOR
    Publication number: 20190117579
    Abstract: Described herein are pharmaceutical formulations of Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one. Also disclosed are methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: December 20, 2018
    Publication date: April 25, 2019
    Inventors: Ching W. Chong, Robert Kuehl, Heow Tan, Harisha Atluri
  • Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor
    Patent number: 10213386
    Abstract: Described herein are pharmaceutical formulations of Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one. Also disclosed are methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Grant
    Filed: May 3, 2018
    Date of Patent: February 26, 2019
    Assignee: Pharmacyclics LLC
    Inventors: Ching W. Chong, Robert Kuehl, Heow Tan, Harisha Atluri
  • PHARMACEUTICAL FORMULATIONS OF A BRUTON'S TYROSINE KINASE INHIBITOR
    Publication number: 20190015340
    Abstract: Described herein are pharmaceutical formulations of Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one. Also disclosed are methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: September 11, 2018
    Publication date: January 17, 2019
    Inventors: Ching W. Chong, Robert Kuehl, Heow Tan, Harisha Atluri
  • Formulations of a Bruton's tyrosine kinase inhibitor
    Patent number: 10105368
    Abstract: Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including novel pharmaceutical formulations thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Grant
    Filed: March 17, 2017
    Date of Patent: October 23, 2018
    Assignee: Pharmacyclics LLC
    Inventors: Harisha Atluri, Ching Wah Chong, Robert Kuehl, Cassandra Shu, Pearl Shwe-Cho Tay, James Francis Hulvat, Alexander Jacob McVey, Ryan Mitchell Minikis
  • HETEROCYCLIC COMPOUNDS AND THEIR USES
    Publication number: 20180273479
    Abstract: Provided are certain pharmaceutical formulations of omecamtiv mecarbil and methods for their preparation and use.
    Type: Application
    Filed: March 20, 2018
    Publication date: September 27, 2018
    Inventors: Mingda Bi, Robert Kuehl
  • PHARMACEUTICAL FORMULATIONS OF A BRUTON'S TYROSINE KINASE INHIBITOR
    Publication number: 20180250234
    Abstract: Described herein are pharmaceutical formulations of Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one. Also disclosed are methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: May 3, 2018
    Publication date: September 6, 2018
    Inventors: Ching W. Chong, Robert Kuehl, Heow Tan, Harisha Atluri
  • Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor
    Patent number: 10010507
    Abstract: Described herein are pharmaceutical formulations of Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one. Also disclosed are methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Grant
    Filed: March 1, 2018
    Date of Patent: July 3, 2018
    Assignee: Pharmacyclics LLC
    Inventors: Ching W. Chong, Robert Kuehl, Heow Tan, Harisha Atluri
  • Heterocyclic compounds and their uses
    Patent number: 9951015
    Abstract: Provided are certain pharmaceutical formulations of omecamtiv mecarbil and methods for their preparation and use.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: April 24, 2018
    Assignee: AMGEN INC.
    Inventors: Mingda Bi, Robert Kuehl
  • Novel Formulations of a Bruton's Tyrosine Kinase Inhibitor
    Publication number: 20180028537
    Abstract: Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including novel pharmaceutical formulations thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: March 17, 2017
    Publication date: February 1, 2018
    Inventors: Harisha Atluri, Ching Wah Chong, Robert Kuehl, Cassandra Shu, Pearl Shwe-Cho Tay, James Francis Hulvat, Alexander Jacob McVey, Ryan Mitchell Minikis
  • Pharmaceutical Formulations of a Bruton's Tyrosine Kinase Inhibitor
    Publication number: 20170258729
    Abstract: Described herein are pharmaceutical formulations of Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one. Also disclosed are methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: March 23, 2017
    Publication date: September 14, 2017
    Inventors: Ching W. Chong, Robert Kuehl, Heow Tan, Harisha Atluri
  • Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor
    Patent number: 9655857
    Abstract: Described herein are pharmaceutical formulations of Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one. Also disclosed are methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: May 23, 2017
    Assignee: Pharmacyclics LLC
    Inventors: Ching W. Chong, Robert Kuehl, Heow Tan, Harisha Atluri